Members of Streptomyces are known to be prolific producers of bioactive compounds, including antibacterials, antioxidants, neuroprotective agents as well as immunomodulatory compounds. Isolated from East Malaysia, Streptomyces monashensis MUSC 1JT (=DSM 103626T =MCCC 1K03221T) was initially described as a novel streptomycete using a polyphasic approach. Based on phylogenetic analyses, the closely strains related to MUSC 1JT were identified as Streptomyces corchorusii DSM 40340T (98.7 %), Streptomyces olivaceoviridis NBRC 3066T (98.7 %), Streptomyces canarius NBRC 13431T (98.6 %), and Streptomyces coacervatus AS-0823T (98.4 %). Seven day fermentative extracts of MUSC 1JT exhibited potent antioxidant activity and significant cytotoxic activity against colon cancer cell lines, thus the strain was selected for whole genome sequencing. The genome size of MUSC 1JT is described to be 10.3 Mbps with G + C content of 71.50%. Based on antiSMASH analysis, the strain possessess great genomic potential, having fifty nine biosynthetic gene clusters related to production of secondary metabolites and antibiotics. Therefore, these results serve a foundation for further in-depth investigation to harness its bioactive potential for the development of highly valuable pharmaceutical products.